Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination.

Chittick GE, Zong J, Begley JA, Alianti JR, Sorbel JJ, Blum MR.

Int J Clin Pharmacol Ther. 2008 Dec;46(12):627-36.

PMID:
19049696
2.
3.

Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.

Vourvahis M, Davis J, Langdon G, Layton G, Fang J, Choo HW, Hansson AG, Tawadrous M.

Antivir Ther. 2013;18(6):745-54. doi: 10.3851/IMP2566. Epub 2013 Apr 4.

PMID:
23558061
4.

Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study.

Shiomi M, Matsuki S, Ikeda A, Ishikawa T, Nishino N, Kimura M, Irie S.

J Clin Pharmacol. 2014 Jun;54(6):640-8. doi: 10.1002/jcph.283. Epub 2014 Mar 18.

5.

Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.

Custodio JM, Yin X, Hepner M, Ling KH, Cheng A, Kearney BP, Ramanathan S.

J Clin Pharmacol. 2014 Apr;54(4):378-85. doi: 10.1002/jcph.210. Epub 2013 Nov 16.

PMID:
24142299
6.
7.

Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.

Huang F, Scholl P, Huang DB, MacGregor TR, Taub ME, Vinisko R, Castles MA, Robinson P.

Basic Clin Pharmacol Toxicol. 2011 Mar;108(3):163-70. doi: 10.1111/j.1742-7843.2010.00636.x. Epub 2010 Oct 27.

8.

Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.

Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM.

Antivir Ther. 2013;18(1):105-13. doi: 10.3851/IMP2413. Epub 2012 Oct 5.

PMID:
23043067
9.

Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.

Frampton JE, Croom KF.

Drugs. 2006;66(11):1501-12; discussion 1513-4.

PMID:
16906786
11.

Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.

Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr, Cotter A, Purswani M; PACTG 394 Study Team.

Antimicrob Agents Chemother. 2011 Dec;55(12):5914-22. doi: 10.1128/AAC.00544-11. Epub 2011 Sep 6.

12.

Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.

Kakuda TN, Schöller-Gyüre M, De Smedt G, Beets G, Aharchi F, Peeters MP, Vandermeulen K, Woodfall BJ, Hoetelmans RM.

HIV Med. 2009 Mar;10(3):173-81. doi: 10.1111/j.1468-1293.2008.00668.x. Epub 2009 Jan 7.

13.

Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers.

Lu C, Jia Y, Chen L, Ding Y, Yang J, Chen M, Song Y, Sun X, Wen A.

J Clin Pharm Ther. 2013 Apr;38(2):136-40. doi: 10.1111/jcpt.12023. Epub 2012 Dec 28.

PMID:
23278367
14.

Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects.

Hu CY, Liu YM, Liu Y, Chen Q, Wang W, Wu K, Dong J, Li J, Jia JY, Lu C, Sun SX, Yu C, Li X.

Clin Ther. 2013 Dec;35(12):1884-9. doi: 10.1016/j.clinthera.2013.09.020. Epub 2013 Oct 19.

PMID:
24148552
15.

The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.

Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, Weizsäcker K, Sadiq ST, Ivanovic J, Giaquinto C, Taylor GP, Moltó J, Burger DM; PANNA network.

AIDS. 2013 Mar 13;27(5):739-48. doi: 10.1097/QAD.0b013e32835c208b.

PMID:
23169329
16.

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C; Partners PrEP Study Team.

Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.

17.

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.

Custodio JM, Chuck SK, Chu H, Cao H, Ma G, Flaherty J, Ling J, Kearney BP.

Pharmacol Res Perspect. 2017 Oct;5(5). doi: 10.1002/prp2.353.

18.

Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.

Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, Mohabeer M, Gazzard B, Boffito M.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):275-81. doi: 10.1097/QAI.0b013e3182829bd0.

PMID:
23274933
19.

Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.

Nirogi R, Bhyrapuneni G, Kandikere V, Muddana N, Saralaya R, Komarneni P, Mudigonda K, Mukkanti K.

Biopharm Drug Dispos. 2012 Jul;33(5):265-77. doi: 10.1002/bdd.1794. Epub 2012 Jun 20.

PMID:
22610784
20.

Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.

Deeks ED, Perry CM.

Drugs. 2010 Dec 3;70(17):2315-38. doi: 10.2165/11203800-000000000-00000. Review.

PMID:
21080746

Supplemental Content

Support Center